About this data
What it is
The FDA publishes its decisions on drugs and medical devices through openFDA. We list approved drug applications and the changes approved to them, 510(k) clearances of devices and premarket approvals (PMA) of higher-risk devices, and match the applicant to a public company when the name lines up. The page opens on new brand-name drugs and biologics: the first approval of a new drug application (NDA) or biologics license application (BLA).
Who files it
The FDA decides; openFDA publishes the FDA's records. The applicant is the company named in the FDA's record for the application.
How current
We check openFDA every day. The FDA refreshes its files on its own schedule, and a decision can appear days to weeks after its date, so the latest approvals may show up late.
Terms
openFDAopenFDA is the FDA's public data service. It publishes the FDA's own records of drug approvals and device decisions. openFDA asks users not to imply that the FDA endorses their product or service: this site is not endorsed by or affiliated with the FDA.NDA and BLAA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original.supplementA later approved change to a drug that is already on the market: a new use, a new dose, a label change or a manufacturing change. Many supplements are minor.generic drugsA generic drug (an ANDA, or abbreviated new drug application) is approved because it matches a drug already on the market. Generics are made by many companies, most of which are not public.510(k)A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval.PMAPremarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.company matchWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.
Worth knowing
This is a record of decisions already made. It is not a calendar of coming decisions: a drug under review does not appear, and we show no review dates. openFDA asks users not to imply that the FDA endorses their product or service: this page is not endorsed by or affiliated with the FDA, and the FDA makes no warranty about the data. It is not for medical decisions. Most applicants, such as generic makers and private device makers, do not match a public company, and a subsidiary or a differently spelled name can be missed, so a row with no ticker may still belong to one. A clearance is not an approval, and many approved supplements are minor.
Not to be confused with
Clinical trial updates: what sponsors report about their studies, not what the FDA decided.

All of this comes from openFDA, the FDA's public data service. This site is not endorsed by or affiliated with the FDA.

FDA decisions per day, last 30 days

010203040Oct 17 · Brand-name drugs and biologics, with supplements: 0Oct 17 · Device clearances and approvals: 0Oct 17Oct 18 · Brand-name drugs and biologics, with supplements: 0Oct 18 · Device clearances and approvals: 1Oct 19 · Brand-name drugs and biologics, with supplements: 4Oct 19 · Device clearances and approvals: 10Oct 20 · Brand-name drugs and biologics, with supplements: 3Oct 20 · Device clearances and approvals: 12Oct 21 · Brand-name drugs and biologics, with supplements: 6Oct 21 · Device clearances and approvals: 18Oct 21Oct 22 · Brand-name drugs and biologics, with supplements: 6Oct 22 · Device clearances and approvals: 15Oct 23 · Brand-name drugs and biologics, with supplements: 7Oct 23 · Device clearances and approvals: 24Oct 24 · Brand-name drugs and biologics, with supplements: 0Oct 24 · Device clearances and approvals: 1Oct 25 · Brand-name drugs and biologics, with supplements: 0Oct 25 · Device clearances and approvals: 1Oct 25Oct 26 · Brand-name drugs and biologics, with supplements: 4Oct 26 · Device clearances and approvals: 17Oct 27 · Brand-name drugs and biologics, with supplements: 5Oct 27 · Device clearances and approvals: 18Oct 28 · Brand-name drugs and biologics, with supplements: 2Oct 28 · Device clearances and approvals: 15Oct 29 · Brand-name drugs and biologics, with supplements: 3Oct 29 · Device clearances and approvals: 27Oct 29Oct 30 · Brand-name drugs and biologics, with supplements: 6Oct 30 · Device clearances and approvals: 32Oct 31 · Brand-name drugs and biologics, with supplements: 0Oct 31 · Device clearances and approvals: 0Nov 1 · Brand-name drugs and biologics, with supplements: 0Nov 1 · Device clearances and approvals: 0Nov 2 · Brand-name drugs and biologics, with supplements: 1Nov 2 · Device clearances and approvals: 0Nov 2Nov 3 · Brand-name drugs and biologics, with supplements: 1Nov 3 · Device clearances and approvals: 0Nov 4 · Brand-name drugs and biologics, with supplements: 3Nov 4 · Device clearances and approvals: 0Nov 5 · Brand-name drugs and biologics, with supplements: 2Nov 5 · Device clearances and approvals: 0Nov 6 · Brand-name drugs and biologics, with supplements: 4Nov 6 · Device clearances and approvals: 0Nov 6Nov 7 · Brand-name drugs and biologics, with supplements: 0Nov 7 · Device clearances and approvals: 0Nov 8 · Brand-name drugs and biologics, with supplements: 0Nov 8 · Device clearances and approvals: 0Nov 9 · Brand-name drugs and biologics, with supplements: 5Nov 9 · Device clearances and approvals: 0Nov 10 · Brand-name drugs and biologics, with supplements: 5Nov 10 · Device clearances and approvals: 0Nov 10Nov 11 · Brand-name drugs and biologics, with supplements: 1Nov 11 · Device clearances and approvals: 0Nov 12 · Brand-name drugs and biologics, with supplements: 0Nov 12 · Device clearances and approvals: 0Nov 13 · Brand-name drugs and biologics, with supplements: 0Nov 13 · Device clearances and approvals: 0Nov 14 · Brand-name drugs and biologics, with supplements: 0Nov 14 · Device clearances and approvals: 0Nov 14Nov 15 · Brand-name drugs and biologics, with supplements: 0Nov 15 · Device clearances and approvals: 0
010203040Oct 17 · Brand-name drugs and biologics, with supplements: 0Oct 17 · Device clearances and approvals: 0Oct 17Oct 18 · Brand-name drugs and biologics, with supplements: 0Oct 18 · Device clearances and approvals: 1Oct 19 · Brand-name drugs and biologics, with supplements: 4Oct 19 · Device clearances and approvals: 10Oct 20 · Brand-name drugs and biologics, with supplements: 3Oct 20 · Device clearances and approvals: 12Oct 21 · Brand-name drugs and biologics, with supplements: 6Oct 21 · Device clearances and approvals: 18Oct 21Oct 22 · Brand-name drugs and biologics, with supplements: 6Oct 22 · Device clearances and approvals: 15Oct 23 · Brand-name drugs and biologics, with supplements: 7Oct 23 · Device clearances and approvals: 24Oct 24 · Brand-name drugs and biologics, with supplements: 0Oct 24 · Device clearances and approvals: 1Oct 25 · Brand-name drugs and biologics, with supplements: 0Oct 25 · Device clearances and approvals: 1Oct 25Oct 26 · Brand-name drugs and biologics, with supplements: 4Oct 26 · Device clearances and approvals: 17Oct 27 · Brand-name drugs and biologics, with supplements: 5Oct 27 · Device clearances and approvals: 18Oct 28 · Brand-name drugs and biologics, with supplements: 2Oct 28 · Device clearances and approvals: 15Oct 29 · Brand-name drugs and biologics, with supplements: 3Oct 29 · Device clearances and approvals: 27Oct 29Oct 30 · Brand-name drugs and biologics, with supplements: 6Oct 30 · Device clearances and approvals: 32Oct 31 · Brand-name drugs and biologics, with supplements: 0Oct 31 · Device clearances and approvals: 0Nov 1 · Brand-name drugs and biologics, with supplements: 0Nov 1 · Device clearances and approvals: 0Nov 2 · Brand-name drugs and biologics, with supplements: 1Nov 2 · Device clearances and approvals: 0Nov 2Nov 3 · Brand-name drugs and biologics, with supplements: 1Nov 3 · Device clearances and approvals: 0Nov 4 · Brand-name drugs and biologics, with supplements: 3Nov 4 · Device clearances and approvals: 0Nov 5 · Brand-name drugs and biologics, with supplements: 2Nov 5 · Device clearances and approvals: 0Nov 6 · Brand-name drugs and biologics, with supplements: 4Nov 6 · Device clearances and approvals: 0Nov 6Nov 7 · Brand-name drugs and biologics, with supplements: 0Nov 7 · Device clearances and approvals: 0Nov 8 · Brand-name drugs and biologics, with supplements: 0Nov 8 · Device clearances and approvals: 0Nov 9 · Brand-name drugs and biologics, with supplements: 5Nov 9 · Device clearances and approvals: 0Nov 10 · Brand-name drugs and biologics, with supplements: 5Nov 10 · Device clearances and approvals: 0Nov 10Nov 11 · Brand-name drugs and biologics, with supplements: 1Nov 11 · Device clearances and approvals: 0Nov 12 · Brand-name drugs and biologics, with supplements: 0Nov 12 · Device clearances and approvals: 0Nov 13 · Brand-name drugs and biologics, with supplements: 0Nov 13 · Device clearances and approvals: 0Nov 14 · Brand-name drugs and biologics, with supplements: 0Nov 14 · Device clearances and approvals: 0Nov 14Nov 15 · Brand-name drugs and biologics, with supplements: 0Nov 15 · Device clearances and approvals: 0

Brand-name drugs and biologics, with supplements Device clearances and approvals

By the FDA's decision date. Generic drugs are left out. The FDA's files can lag a decision by days to weeks, so the most recent days fill in later.

Latest FDA decisions

Reset

Showing: ticker INCY · Everything

Latest FDA decisions
DecidedProductApplicantWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.DecisionA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original. A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval. Premarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.FDA page
Jul 20, 2026JAKAFI XR
RUXOLITINIB PHOSPHATE
INCY
Incyte Corp
New drug (NDA), supplement
Labeling
NDA217180 ↗
Letter or label ↗
Jul 20, 2026JAKAFI
RUXOLITINIB PHOSPHATE
INCY
Incyte Corp
New drug (NDA), supplement
Labeling
NDA202192 ↗
Letter or label ↗
Jun 30, 2026OPZELURA
RUXOLITINIB PHOSPHATE
INCY
Incyte Corp
New drug (NDA), supplement
Labeling
NDA215309 ↗
May 18, 2026ZYNYZ
RETIFANLIMAB-DLWR
INCY
Incyte Corp
Biologic (BLA), supplement
Efficacy
BLA761334 ↗
May 1, 2026JAKAFI XR
RUXOLITINIB PHOSPHATE
INCY
Incyte Corp
New drug (NDA)
Type 5 - New Formulation or New Manufac…
NDA217180 ↗
Mar 30, 2026ZYNYZ
RETIFANLIMAB-DLWR
INCY
Incyte Corp
Biologic (BLA), supplement
Efficacy
BLA761334 ↗
Dec 17, 2025ZYNYZ
RETIFANLIMAB-DLWR
INCY
Incyte Corp
Biologic (BLA), supplement
Efficacy
BLA761334 ↗
Sep 18, 2025OPZELURA
RUXOLITINIB PHOSPHATE
INCY
Incyte Corp
New drug (NDA), supplement
Efficacy
NDA215309 ↗
May 15, 2025ZYNYZ
RETIFANLIMAB-DLWR
INCY
Incyte Corp
Biologic (BLA), supplement
Efficacy
BLA761334 ↗
Aug 14, 2024NIKTIMVO
axatilimab-csfr
INCY
Incyte Corp
Biologic (BLA)
Type 1 - New Molecular Entity
BLA761411 ↗
Apr 22, 2024ZYNYZ
RETIFANLIMAB-DLWR
INCY
Incyte Corp
Biologic (BLA), supplement
Labeling
BLA761334 ↗
Mar 22, 2023ZYNYZ
RETIFANLIMAB-DLWR
INCY
Incyte Corp
Biologic (BLA)
Type 1 - New Molecular Entity
BLA761334 ↗
Mar 13, 2023OPZELURA
RUXOLITINIB PHOSPHATE
INCY
Incyte Corp
New drug (NDA), supplement
Labeling
NDA215309 ↗
Jan 31, 2023JAKAFI
RUXOLITINIB PHOSPHATE
INCY
Incyte Corp
New drug (NDA), supplement
Labeling
NDA202192 ↗
Dec 19, 2022JAKAFI
RUXOLITINIB PHOSPHATE
INCY
Incyte Corp
New drug (NDA), supplement
Efficacy
NDA202192 ↗
Aug 26, 2022PEMAZYRE
PEMIGATINIB
INCY
Incyte Corp
New drug (NDA), supplement
Efficacy
NDA213736 ↗
Jul 18, 2022OPZELURA
RUXOLITINIB PHOSPHATE
INCY
Incyte Corp
New drug (NDA), supplement
Efficacy
NDA215309 ↗
Sep 27, 2021JAKAFI
RUXOLITINIB PHOSPHATE
INCY
Incyte Corp
New drug (NDA), supplement
Labeling
NDA202192 ↗
Sep 22, 2021JAKAFI
RUXOLITINIB PHOSPHATE
INCY
Incyte Corp
New drug (NDA), supplement
Efficacy
NDA202192 ↗
Sep 21, 2021OPZELURA
RUXOLITINIB PHOSPHATE
INCY
Incyte Corp
New drug (NDA)
Type 10 - New Indication Submitted as D…
NDA215309 ↗
Letter or label ↗
Feb 23, 2021PEMAZYRE
PEMIGATINIB
INCY
Incyte Corp
New drug (NDA), supplement
Labeling
NDA213736 ↗
Letter or label ↗
Apr 17, 2020PEMAZYRE
PEMIGATINIB
INCY
Incyte Corp
New drug (NDA)
Type 1 - New Molecular Entity
NDA213736 ↗
Letter or label ↗
Jan 14, 2020JAKAFI
RUXOLITINIB PHOSPHATE
INCY
Incyte Corp
New drug (NDA), supplement
Labeling
NDA202192 ↗
Letter or label ↗
May 24, 2019JAKAFI
RUXOLITINIB PHOSPHATE
INCY
Incyte Corp
New drug (NDA), supplement
Efficacy
NDA202192 ↗
Letter or label ↗
Oct 26, 2018JAKAFI
RUXOLITINIB PHOSPHATE
INCY
Incyte Corp
New drug (NDA), supplement
Labeling
NDA202192 ↗
Letter or label ↗
Dec 6, 2017JAKAFI
RUXOLITINIB PHOSPHATE
INCY
Incyte Corp
New drug (NDA), supplement
Labeling
NDA202192 ↗
Oct 10, 2017JAKAFI
RUXOLITINIB PHOSPHATE
INCY
Incyte Corp
New drug (NDA), supplement
Efficacy
NDA202192 ↗
Letter or label ↗
Mar 10, 2016JAKAFI
RUXOLITINIB PHOSPHATE
INCY
Incyte Corp
New drug (NDA), supplement
Efficacy
NDA202192 ↗
Letter or label ↗
Dec 2, 2015JAKAFI
RUXOLITINIB PHOSPHATE
INCY
Incyte Corp
New drug (NDA), supplement
Manufacturing (CMC)
NDA202192 ↗
Oct 6, 2015JAKAFI
RUXOLITINIB PHOSPHATE
INCY
Incyte Corp
New drug (NDA), supplement
Manufacturing (CMC)
NDA202192 ↗

30 items, most recent first (up to 50). Each row links to the FDA's page for the application, clearance or approval. Updated Nov 15, 2026, 6:46 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates